Literature DB >> 16636339

Irinogenetics: what is the right star?

Federico Innocenti, Everett E Vokes, Mark J Ratain.   

Abstract

Mesh:

Substances:

Year:  2006        PMID: 16636339     DOI: 10.1200/JCO.2005.05.2464

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  14 in total

Review 1.  Uridine 5'-diphospho-glucuronosyltransferase genetic polymorphisms and response to cancer chemotherapy.

Authors:  Jacqueline Ramírez; Mark J Ratain; Federico Innocenti
Journal:  Future Oncol       Date:  2010-04       Impact factor: 3.404

2.  All You Need to Know About UGT1A1 Genetic Testing for Patients Treated With Irinotecan: A Practitioner-Friendly Guide.

Authors:  Spinel Karas; Federico Innocenti
Journal:  JCO Oncol Pract       Date:  2021-12-03

3.  Predictive and prognostic markers in colorectal cancer.

Authors:  Peter M Wilson; Robert D Ladner; Heinz-Josef Lenz
Journal:  Gastrointest Cancer Res       Date:  2007-11

Review 4.  Pharmacogenetics of solid tumors: directed therapy in breast, lung, and colorectal cancer: a paper from the 2008 william beaumont hospital symposium on molecular pathology.

Authors:  Christine L H Snozek; Dennis J O'Kane; Alicia Algeciras-Schimnich
Journal:  J Mol Diagn       Date:  2009-07-30       Impact factor: 5.568

5.  Comprehensive pharmacogenetic analysis of irinotecan neutropenia and pharmacokinetics.

Authors:  Federico Innocenti; Deanna L Kroetz; Erin Schuetz; M Eileen Dolan; Jacqueline Ramírez; Mary Relling; Peixian Chen; Soma Das; Gary L Rosner; Mark J Ratain
Journal:  J Clin Oncol       Date:  2009-04-06       Impact factor: 44.544

6.  UGT1A1*6, 1A7*3, and 1A9*22 genotypes predict severe neutropenia in FOLFIRI-treated metastatic colorectal cancer in two prospective studies in Japan.

Authors:  Shoichi Hazama; Hideyuki Mishima; Ryouichi Tsunedomi; Yusuke Okuyama; Takeshi Kato; Ken-ichi Takahashi; Hiroshi Nozawa; Hideaki Ando; Michiya Kobayashi; Hiroyoshi Takemoto; Naoki Nagata; Shinsuke Kanekiyo; Yuka Inoue; Yoshihiko Hamamoto; Yusuke Fujita; Yuji Hinoda; Naoko Okayama; Koji Oba; Jun-ichi Sakamoto; Masaaki Oka
Journal:  Cancer Sci       Date:  2013-10-27       Impact factor: 6.716

7.  Pharmacokinetic analysis of irinotecan plus bevacizumab in patients with advanced solid tumors.

Authors:  Crystal S Denlinger; Rebecca Blanchard; Lu Xu; Coen Bernaards; Samuel Litwin; Cynthia Spittle; Daniel J Berg; Susan McLaughlin; Maryann Redlinger; Andrew Dorr; Julie Hambleton; Scott Holden; Anne Kearns; Sara Kenkare-Mitra; Bert Lum; Neal J Meropol; Peter J O'Dwyer
Journal:  Cancer Chemother Pharmacol       Date:  2009-05-05       Impact factor: 3.333

8.  All You Need to Know About DPYD Genetic Testing for Patients Treated With Fluorouracil and Capecitabine: A Practitioner-Friendly Guide.

Authors:  Federico Innocenti; Sarah C Mills; Hanna Sanoff; Joseph Ciccolini; Heinz-Josef Lenz; Gerard Milano
Journal:  JCO Oncol Pract       Date:  2020-11-16

9.  Polymorphisms of UGT1A1*6, UGT1A1*27 & UGT1A1*28 in three major ethnic groups from Malaysia.

Authors:  L K Teh; H Hashim; Z A Zakaria; M Z Salleh
Journal:  Indian J Med Res       Date:  2012-08       Impact factor: 2.375

10.  Adaptive evolution of multiple-variable exons and structural diversity of drug-metabolizing enzymes.

Authors:  Can Li; Qiang Wu
Journal:  BMC Evol Biol       Date:  2007-05-02       Impact factor: 3.260

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.